科研论文-康宁杰瑞

科研论文

截至目前，康宁杰瑞拥有或共同拥有全球41项与技术平台及产品管线相关的专利授权。研发团队在具有重要影响力的期刊上发表研究论文多篇。

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
了解详情
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
了解详情
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
了解详情
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4
了解详情

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Envafolimab is a novel fusion of a humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection. This study explored the safety and feasibility of subcutaneo...

发表于:
The Oncologist

2021;26:e1514–e1525
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Monoclonal antibodies targeting programmed death ligand 1 (PD‑L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI‑H) tumors must be delivered b...

发表于:
Journal of Hematology & Oncology

2021, 14(1): 95.
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play critical roles ...

发表于:
Autophagy.

2019 Jul;15(7):1258-1279.
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8+ T cells. However, it remains elusive how ...

发表于:
Cancer Cell.

2019 Jun 10;35(6):901-915.e4.
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediate...

发表于:
Molecular Cancer Therapeutics.

2019 Jan;18(1):100-111.
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

Recently, various immuno-PET tracers based on monoclonal antibodies (mAbs),engineered scaffold proteins, and peptides were developed to target either programmed cell death protein 1 (PD-1) or programm...

发表于:
Molecular Pharmaceutics.

2018 Apr 2;15(4):1674-1681.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blockingnegative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrationsconsiderably higher than plasma levels achieve...

发表于:
Cell Research.

2018 Apr;28(4):416-432.
A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line

Combinations of different antibodies have been shown to be more effective formanaging certain diseases than monotherapy. Co-expression of the antibody mixturein a single cell line is key to reducing ....

发表于:
Journal of Biological Chemistry.

2017 Oct 27;292(43):17885.
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achievedunprecedented success in cancer treatment over the last few years. Atezolizumabis the first PD-L1 monoclonal antibody approved...

发表于:
Oncotarget.

2017 Oct 6;8(52):90215-90224.
Structural basis of a novel heterodimeric Fc for bispecific antibody production

Bispecific antibodies provide an efficient tool for combinational clinicaltherapy. Here we have engineered a heterodimeric Fc for bispecific antibodiesproduction by combining the knob-into-hole and .....

发表于:
Oncotarget.

2017 May 2;8(31):51037-51049.

1 2 3

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Envafolimab is a novel fusion of a humanized single-domain PD-L1 antibody and human IgG1 Fc fragment formulated for subcutaneous injection. This study explored the safety and feasibility of subcutaneo...

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Monoclonal antibodies targeting programmed death ligand 1 (PD‑L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI‑H) tumors must be delivered b...

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play critical roles ...

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8+ T cells. However, it remains elusive how ...

Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediate...

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

Recently, various immuno-PET tracers based on monoclonal antibodies (mAbs),engineered scaffold proteins, and peptides were developed to target either programmed cell death protein 1 (PD-1) or programm...

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blockingnegative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrationsconsiderably higher than plasma levels achieve...

A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line

Combinations of different antibodies have been shown to be more effective formanaging certain diseases than monotherapy. Co-expression of the antibody mixturein a single cell line is key to reducing ....

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achievedunprecedented success in cancer treatment over the last few years. Atezolizumabis the first PD-L1 monoclonal antibody approved...

Structural basis of a novel heterodimeric Fc for bispecific antibody production

Bispecific antibodies provide an efficient tool for combinational clinicaltherapy. Here we have engineered a heterodimeric Fc for bispecific antibodiesproduction by combining the knob-into-hole and .....